• Autonomy (sponsor: Janssen): anti-tau antibody; monthly IV infusion in prodromal Alzheimer’s disease (MCI with evidence of tauopathy). PI: Pr Bernard Hanseeuw. Actively recruiting. https://clinicaltrials.gov/ct2/show/NCT04619420

• Skyline (sponsor: Roche): anti-amyloid antibody; bi-monthly subcutaneous injection of Gantenerumab in asymptomatic adults older than 60 with evidence of amyloidosis after blood test and PET scanning. PI: Pr Bernard Hanseeuw. Starting date: Summer 2022. https://clinicaltrials.gov/ct2/show/NCT05256134

• A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer’s Disease (AD) (NCT04867616) (PI: Rik Vandenberghe, UZ Leuven)
• A Study of JNJ-63733657 in Participants With Early Alzheimer’s Disease (Autonomy)(NCT04619420) (PI: Rik Vandenberghe, UZ Leuven)
• A Research Study Investigating Semaglutide in People With early Alzheimer’s Disease (EVOKE Plus) (NCT04777409) (PI: Rik Vandenberghe, UZ Leuven)

Frontotemporal degeneration:

• Phase 1/2 Clinical Trial of PR006 in Patients With Frontotemporal Dementia with Progranulin Mutations (FTD-GRN) (PROCLAIM) (NCT04408625) (PI: Rik Vandenberghe, UZ Leuven)
• A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3) (NCT04374136) (PI: Rik Vandenberghe, UZ Leuven)
• Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD) (FOCUS-C9) (NCT04931862) (PI: Rik Vandenberghe en Philip Van Damme, UZ Leuven)

• Fahr’s disease:

  • Treatment of ectopic celcification in Fahr’s disease or syndrome  (CALCIFADE)

 Neuromuscular Disease:

Pompe’s disease:

• Fase 3 studie met intraveneuze ATB200 en perorale AT2221 behandeling, bij de ziekte van Pompe (NCT04138277) (PI: Kristl Claeys, UZ Leuven) 
• Fase 3 studie met intraveneuze avalglucosidase-alfa of alglucosidase-alfa behandeling, bij de ziekte van Pompe (NCT02782741) (PI: Kristl Claeys, UZ Leuven) 
•  Register voor patiënten met de ziekte van Pompe (NCT00231400) (PI: Kristl Claeys, UZ Leuven) 

Limb-girdle muscle dystrophy (LGMD):

• Natuurlijke verloop studie bij limb-girdle spierdystrofie type sarcoglycanopathieën (NCT04475926) (PI: Kristl Claeys, UZ Leuven) 

Mitochondrial myopathy:

• Fase 2/3 studie met perorale REN001 behandeling bij primaire mitochondriale myopathie (PMM) (NCT04535609) (PI: Kristl Claeys, UZ Leuven) 
• Fase 2/3 open label lange termijn studie met perorale REN001 behandeling bij primaire mitochondriale myopathie (NCT05267574) (PI: Kristl Claeys, UZ Leuven)
• Fase 3 studie met perorale KL1333 behandeling bij primaire mitochondriale myopathie (PMM) (NCT05650229) (PI: Kristl Claeys, UZ Leuven)

transthyretine (TTR) polyneuropathy:

• Fase 3 studie met subcutane ALN-TTRSC02 behandeling, bij erfelijke transthyretine polyneuropathie (hATTR Amyloïdose) (NCT03759379) (PI: Kristl Claeys, UZ Leuven) 

Charcot-Marie-Tooth neuropathy (CMT):

• Fase 3 studie met perorale PXT3003 behandeling, bij Charcot-Marie-Tooth neuropathie Type 1A (CMT1A) (NCT04762758) (PI: Kristl Claeys, UZ Leuven) 

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP):

• Fase 2 studie met subcutane Efgartigimod behandeling, bij patiënten met CIDP (NCT04281472) (PI: Kristl Claeys, UZ Leuven) 
•  Fase 2 lange-termijn studie met subcutane Efgartigimod behandeling, bij patiënten met CIDP (NCT04280718) (PI: Kristl Claeys, UZ Leuven) 

Myasthenia gravis:

• Fase 3 studie met intraveneuze Nipocalimab behandeling, bij veralgemeende myasthenia gravis (NCT04951622) (PI: Kristl Claeys, UZ Leuven) 
•  Fase 3 studie met intraveneuze Efgartigimod behandeling, bij veralgemeende myasthenia gravis (NCT04980495) (PI: Kristl Claeys, UZ Leuven) 
•  Register voor patiënten met myasthenia gravis (NCT04176211) (PI: Kristl Claeys, UZ Leuven) 
• https://www.uzleuven.be/nl/neurologie/neuromusculair-referentiecentrum-nmrc/klinische-studies-neuromusculaire-ziekten/spierziekten-neuropathieen-en-myasthenia-gravis

Inflammatoire myopathieën/Myositis:

• A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis (NCT05695950) (PI: Kristl Claeys, UZ Leuven)

Spinale Musculaire Atropfie (SMA):

• A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis (NCT05695950) (PI: Kristl Claeys, UZ Leuven)

Fibrodysplasia ossificans progressiva (FOP):

• A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis (NCT05695950) (PI: Kristl Claeys, UZ Leuven)

Amyotrophic lateral sclerosis (ALS):

• A multicenter, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of FAB122 in patients with Amyotrophic Lateral Sclerosis (ADORE) (2020-003376-40) (PI: Philip Van Damme, UZ Leuven) 
•  A study of BIIB067 when initiated in Clinically Presymptomatic Adults with a confirmed superoxide dismutase 1 mutation (ATLAS) (NCT04856982) (PI: Philip Van Damme, UZ Leuven) 
•  A study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS) (COURAGE) (NCT04944784) (PI: Philip Van Damme, UZ Leuven) 
•  A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants with Fused in Sarcoma Mutations (FUS-ALS) (FUSION) (NCT04768972) (PI: Philip Van Damme, UZ Leuven) 
•  A multi-arm, Adaptive, Group-sequential trial NETwork to evaluate drug efficacy in patients with Amyotrophic Lateral Sclerosis (ALS) (MAGNET) (2020-000579-19) (PI: Philip Van Damme, UZ Leuven) 

Epilepsie:

• Multimodal profiling of people with epilepsy to determine which signals are clinically useful for long-term home monitoring (NCT04642105) (PI: Wim Van Paesschen, UZ Leuven)